ALS biomarker go Amydis has secured NIH support to develop eye-based tests for neurodegenerative diseases, including ALS, presenting a strong entry point for partnerships with research labs, pharma, and contract research organizations focusing on ALS biomarkers and non-invasive diagnostics.

TDP-43 detection Development of fluorescent ocular tracers targeting pathological proteins like TDP-43 offers a unique, non-invasive imaging modality that could be licensed or co-developed with ophthalmology and neurology stakeholders seeking early biomarkers for brain and systemic diseases.

Alzheimer's retinal biomarkers Ongoing work on retinal biomarkers for Alzheimer's, supported by NIH funding, creates potential for collaborations with biopharma and academic centers pursuing diagnostic tools, companion diagnostics, and AI-driven health insights from ocular data.

Phase 2 funding Recent Phase 2 funding of 2.5 million USD from the National Institute on Aging indicates validation momentum and de-risked technology; this can facilitate co-development deals, grant-backed partnerships, and licensing opportunities with larger biotech companies.

Multi-omics data platform Amydis is building a multi-omics eye biomarker data warehouse to power AI-enabled health insights; this positions potential collaboration with data science platforms, diagnostics developers, and health analytics firms seeking integrated eye-based biomarkers and scalable AI tools.